The European Society of Cardiology (ESC) together with the European Respiratory Society (ERS) recently launched a new treatment algorithm for pulmonary arterial hypertension in its updated pulmonary hypertension guidelines. The amended protocol aims to provide patients with the best chance of a positive clinical outcome despite being diagnosed with an untreatable, highly debilitating, and limiting disease.

A research journal recently reviewed the use of balloon pulmonary angioplasty (BPA), a new option for people with inoperable chronic thromboembolic pulmonary arterial hypertension. The work, titled “Balloon pulmonary angioplasty for inoperablechronic thromboembolic pulmonary hypertension“ appeared in the July 7, 2015 issue ofCurrent Opinion in Pulmonary Medicine. Although the method has not been widely used due to fears and evidence that it can in some cases cause death, studies conducted in 2001 indicated that it may be a promising, reliable technique. Recent research out of Japan and Norway are supporting these claims, although researchers admit that further research is still needed.

Researchers at Leiden University Medical Center in The Netherlands recently published in the journal Diagnostic and Interventional Radiology a review on the value of computed tomography (CT) as a diagnostic tool for pulmonary embolism. The study is entitled “The role of computed tomography in the diagnosis of acute and chronic pulmonary embolism.”

Patients with pulmonary hypertension may be surprised to know that the disease can sometimes be accompanied by the complication known as thromboembolic pulmonary hypertension (CTEPH). Pulmonary embolisms are the root cause of CTEPH because a pulmonary embolism (a blood clot in the lungs) that fails to be degraded via thromboembolysis can become lodged in blood vessels leading to the lungs and occlude blood flow. Individuals without any history of pulmonary embolisms are susceptible to CTEPH, making it important to understand the pathophysiology, risks factors, and signs of CTEPH.

As the supplier of the body’s blood, the heart must also supply its own blood to keep itself nourished and oxygenated. The heart’s blood supply comes from the coronary arteries, which receive oxygenated blood from the pulmonary veins. Normally, the heart receives enough oxygenated blood, but with chronic thromboembolic pulmonary hypertension (CTEPH) is present, a clot may obstruct blood flow.

The American Heart Association (AHA) and American Thoracic Society (ATS) have issued new guidelines pertaining to Pediatric Pulmonary Hypertension. The revisions come as a result of collaboration between the agencies and were developed in a joint effort by an interdisciplinary team of 27 experienced clinicians and clinician-scientists in a review of the current literature in which they analyzed data from more than 600 studies and made recommendations on diagnosis, evaluation, and treatment of pediatric pulmonary hypertension.

The research team, chaired by Steven H. Abman, MD of Children’s Hospital, Colorado, with co-chairs Georg Hansmann, MD, PhD, FAHA of the Department of Pediatric Cardiology and Critical Care at Hannover Medical School, Germany, and Stephen L. Archer, MD, FAHA, Head of Medicine at Queen’s University, Kingston Ontario, Canada notes that pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic diseases in neonates, infants, and older children and contributes to significant morbidity and mortality. However, they observe that current approaches to caring for pediatric pulmonary hypertension patients have been limited by lack of consensus guidelines from experts in the field. Accordingly, the new guidelines incorporate the results of the research team’s extensive literature reviews, discussions, and formal scoring of recommendations for the care of children with pulmonary hypertension.ons for the care of children with pulmonary hypertension.

Satisfactory surgical outcomes reported, even in severe PH cases, if best practices are followed

Recently published research reveals that orthopedic (musculoskeletal) surgery in patients with pulmonary hypertension (PH), while challenging, is feasible and offers decent outcomes even in severe stages of the disease, provided proper care is given. The paper entitled “Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations“ was published in the GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW journal.

Page 1 of 2

About Us

The Saudi Association for Pulmonary Hypertension (SAPH) is a medical and research national group of many medical specialists, who shared a common interest in the field of pulmonary vascular disease. The main goal for SAPH is to increase the awareness and the knowledge of pulmonary vascular diseases in the society and between the medical professionals.

The Saudi Association for Pulmonary Hypertension (SAPH) is a Subsidiary of The

Saudi Association for PH

STS office (Exit 11 & the Airport Road)

Riyadh, Saudi Arabia

P. O. Box 106911
Riyadh 11676
Saudi Arabia

Tel:+966-11-2488966
Fax: +966-11-2487431
Mobile:+966506426704

We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…